Stockscreener 앱 받기
37.64
3.04%
1.11
시간 외 거래:
37.64
전일 마감가:
$36.53
열려 있는:
$36.3
하루 거래량:
199.77K
Relative Volume:
0.66
시가총액:
$1.68B
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+6.78%
1개월 성능:
+3.58%
6개월 성능:
+79.32%
1년 성능:
+89.53%
1일 변동 폭
$36.07
$38.86
1주일 범위
$34.87
$38.91
52주 변동 폭
$7.255
$45.00
Sionna Therapeutics Inc Stock (SION) Company Profile
명칭
Sionna Therapeutics Inc
전화
617-819-2020
주소
21 HICKORY DRIVE, SUITE 500, WALTHAM
Compare SION vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SION
Sionna Therapeutics Inc
|
37.64 | 1.63B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Sionna Therapeutics Inc Stock (SION) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-01 | 다운그레이드 | RBC Capital Mkts | Sector Perform → Underperform |
| 2025-11-19 | 개시 | BTIG Research | Buy |
| 2025-09-03 | 개시 | RBC Capital Mkts | Sector Perform |
| 2025-09-03 | 개시 | Raymond James | Strong Buy |
| 2025-03-04 | 개시 | Guggenheim | Buy |
| 2025-03-04 | 개시 | Stifel | Buy |
| 2025-03-04 | 개시 | TD Cowen | Buy |
모두보기
Sionna Therapeutics Inc 주식(SION)의 최신 뉴스
SION: NBD1 stabilizer programs target major CF mutations, with pivotal data expected mid-2026 - TradingView
What’s the MACD signal for Sionna Therapeutics Inc.July 2025 Outlook & Risk Adjusted Buy/Sell Alerts - mfd.ru
Volume Recap: Should you avoid Sionna Therapeutics Inc stock right nowEarnings Miss & Growth-Oriented Investment Plans - baoquankhu1.vn
Orbimed Advisors Llc Sells 29,063 Shares of Sionna Therapeutics (NASDAQ:SION) Stock - Defense World
Sionna Therapeutics (NASDAQ:SION) Shares Down 14.6% on Insider Selling - Defense World
Sionna Therapeutics (NASDAQ:SION) Trading Down 14.6% Following Insider Selling - MarketBeat
OrbiMed Advisors LLC sells Sionna Therapeutics (SION) stock worth $1.37m - Investing.com
OrbiMed Advisors LLC sells Sionna Therapeutics (SION) stock worth $1.37m By Investing.com - Investing.com South Africa
Thompson Peter a. sells Sionna Therapeutics (SION) shares for $1.37m By Investing.com - Investing.com South Africa
Thompson Peter a. sells Sionna Therapeutics (SION) shares for $1.37m - Investing.com India
Sionna Therapeutics (NASDAQ:SION) Director Orbimed Advisors Llc Sells 29,063 Shares - MarketBeat
Sionna Therapeutics to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 - markets.businessinsider.com
Orbimed Advisors Llc Sells 1,890 Shares of Sionna Therapeutics (NASDAQ:SION) Stock - MarketBeat
Support Test: Whats the outlook for Sionna Therapeutics Incs sectorTrade Risk Summary & Smart Allocation Stock Reports - baoquankhu1.vn
Sionna Therapeutics, Inc. (NASDAQ:SION) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
TPG GP A, LLC Reduces Stake in Sionna Therapeutics Inc - GuruFocus
Sionna Therapeutics, Inc. (SION) Stock Analysis: Biotech’s Promising Prospects with 5.7% Upside Potential - DirectorsTalk Interviews
Sionna Therapeutics (SION) 10% owners sell $10 million in stock By Investing.com - Investing.com South Africa
Major Stake Unloaded in Sionna Therapeutics Sparks Fresh Market Buzz - TipRanks
Tpg Gp A, Llc Sells 250,000 Shares of Sionna Therapeutics (NASDAQ:SION) Stock - MarketBeat
Sionna Therapeutics (SION) 10% owners sell $10 million in stock - Investing.com
Sionna Therapeutics (NASDAQ:SION) Shares Gap DownHere's Why - MarketBeat
Sionna Therapeutics, Inc. (SION) Stock Analysis: Exploring a 7.39% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Aug Sentiment: Should you avoid Sionna Therapeutics Inc stock right now - baoquankhu1.vn
Sionna Therapeutics Chief Legal Officer Caps Off Strong 2025 with Sale of Over 10,000 Shares - AOL.com
Sionna Therapeutics (NASDAQ:SION) Stock Price Up 8.1%Here's Why - MarketBeat
Multiple Shots on Goal in Cystic Fibrosis: Sionna’s NBD1-Targeted Pipeline and 2026 Clinical Readouts Drive Buy Thesis and $58 DCF-Based Target - TipRanks
BTIG Research Reiterates Buy Rating for Sionna Therapeutics (NASDAQ:SION) - MarketBeat
SION: Advancing NBD1 stabilizers to transform CF care, with key data expected mid-2026 - TradingView
SION: First-in-class NBD1 stabilizers target full CFTR correction, with pivotal data expected mid-2026 - TradingView — Track All Markets
Sionna Therapeutics (NASDAQ:SION) Stock Price Down 10.1%Here's What Happened - MarketBeat
Assessing Sionna Therapeutics (SION) Valuation After Recent Share Price Swings And Premium P/B Multiple - Yahoo Finance
Sionna Therapeutics Advances Cystic Fibrosis Treatment with New Study - MSN
Sionna Therapeutics, Inc. (SION) Stock Analysis: A 27.73% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Assessing Sionna Therapeutics (SION) Valuation After A Sharp Share Price Move And Elevated Price To Book Ratio - Sahm
Market Recap: How Sionna Therapeutics Inc. stock compares to industry benchmarks2025 Sector Review & Trade Opportunity Analysis - Улправда
Is Sionna Therapeutics Inc. stock positioned for long term growthPortfolio Value Summary & Smart Money Movement Tracker - Улправда
Sionna Therapeutics (NASDAQ:SION) Trading Up 7.7%Here's Why - MarketBeat
Sionna Therapeutics, Inc. (NASDAQ:SION) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Sionna Therapeutics (NASDAQ:SION) Shares Down 7.5%What's Next? - MarketBeat
Sionna Therapeutics, Inc. (NASDAQ:SION) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Orbimed Advisors LLC Reduces Stake in Sionna Therapeutics Inc - GuruFocus
Raymond James raises Sionna Therapeutics stock price target on CF drug potential - Investing.com Canada
Sionna Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
A Sionna Therapeutics (SION) Insider Sold 33,000 Shares for $1.5 Million - AOL.com
A Sionna Therapeutics (SION) Insider Sold 33,000 Shares for $1.5 Million - The Motley Fool
Sionna Therapeutics Insider Sold Shares Worth $1,486,010, According to a Recent SEC Filing - marketscreener.com
Sionna Therapeutics Inc (SION) 재무 분석
Sionna Therapeutics Inc (SION)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Sionna Therapeutics Inc 주식 (SION) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Thompson Peter A. | Director |
Feb 02 '26 |
Sale |
44.57 |
1,890 |
84,237 |
3,559,765 |
| ORBIMED ADVISORS LLC | Director |
Feb 03 '26 |
Sale |
44.58 |
29,063 |
1,295,629 |
3,530,702 |
| ORBIMED ADVISORS LLC | Director |
Feb 02 '26 |
Sale |
44.57 |
1,890 |
84,237 |
3,559,765 |
| TPG GP A, LLC | 10% Owner |
Jan 22 '26 |
Sale |
40.00 |
250,000 |
10,000,000 |
6,494,962 |
1.24%
0.19%
자본화:
|
볼륨(24시간):